产品说明书

GP130 receptor agonist-1

Print
Chemical Structure| 339303-87-6 同义名 : Ucla gp130 2
CAS号 : 339303-87-6
货号 : A670924
分子式 : C15H11FN2S
纯度 : 99%+
分子量 : 270.325
MDL号 : MFCD00784992
存储条件:

粉末 Inert atmosphere,Room Temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 105 mg/mL(388.42 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
描述 P-glycoprotein (P-gp) is an efflux transporter that influences the pharmacokinetics (PK) of various compounds[1]. P-glycoprotein is a well-identified membrane transporter with capability to efflux drug molecules out of the cancer cell leading to reduced efficiency of chemotherapy. Cancer cells upregulate P-gp expression as an adaptive response to evade chemotherapy mediated cell death[2]. Permeability glycoprotein (P-gp) mediates the export of drugs from cells located in the small intestine, blood-brain barrier, hepatocytes, and kidney proximal tubule, serving a protective function for the body against foreign substances[3]. N-(4-Fluorophenyl)-4-phenyl-2-thiazolami (UCLA GP130 2) is a potent, brain-penetrant and orally active GP130 receptor agonist. UCLA GP130 2 treatment showed a 2-fold increase in phosphorylation of STAT3 within 10 min at its regulatory Tyr705 site in SH-SY5Y cells. UCLA GP130 2 treatment increases phosphorylation of AKT at its regulatory Thr308 site and phosphorylation of ERK1/2 at its regulatory Thr202/Tyr204 site in the serum free media condition in SH-SY5Y cells, and in primary cortical neurons. For UCLA GP130 2, mice are dosed orally at 10 or 30 mg/kg, or injected subcutaneously at 10 mg/kg, and euthanized after 1, 2, 4, 6, and 8 h post dose. At 2 h after SQ delivery at 10 mg/kg the brain Cmax is 161 ng/g while dosing at 30 mg/kg orally, results in the brain Cmax of 156 ng/g (0.57 μM). The brain to plasma ratio for 2 is ∼4:1 for oral 30 mg/kg and ∼7.5:1 for 10 mg/kg SQ injection[4].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.70mL

0.74mL

0.37mL

18.50mL

3.70mL

1.85mL

36.99mL

7.40mL

3.70mL

参考文献

[1]Mohamed Elmeliegy,et al. Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies. Clin Pharmacokinet. 2020 Jun;59(6):699-714.

[2]Kianna Robinson,et al. Perplexing Role of P-Glycoprotein in Tumor Microenvironment. Front Oncol.2020 Mar 5;10:265.

[3]Jeffrey D Wessler,et al. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol. 2013 Jun 25;61(25):2495-502.

[4]Mohammad Parvez Alam,et al. A Small Molecule Mimetic of the Humanin Peptide as a Candidate for Modulating NMDA-Induced Neurotoxicity. ACS Chem Neurosci. 2018 Mar 21;9(3):462-468.